



**Multimeric Biotherapeutics, Inc.**  
**(“MultimericBio”)**  
***“Unlocking the potential of the TNF SuperFamily Ligands”***

**San Diego company Multimeric Biotherapeutics, Inc. formed as a Delaware C Corp.**

Feb. 8, 2008, San Diego, CA – The Division of Corporations of the State of Delaware has granted C Corp status to Multimeric Biotherapeutics, Inc. of San Diego, CA. The company was founded to spinout technology developed at the University of California San Diego by its scientific founder, Richard S. Kornbluth, M.D., Ph.D., Associate Professor of Medicine at UCSD. The company will be based in San Diego.

As its initial technology, MultimericBio will develop a platform technology for producing TNF SuperFamily (TNFSF) molecules as highly active, many trimer molecules. TNFSFs are trimeric proteins that fold into tulip shape. They are implicated in a variety of diseases. Currently over \$8 billion/year is spent on blockers of TNF, the prototypic member of the superfamily. However, no member of this molecular family has developed for use as a positive factor. In part, this was due to a failure to recognize that many TNFSFs are inactive as single trimers but rather must be presented as many-trimer multimers to be fully active. The company’s logo represents its technology for producing such highly active molecules.

The multimeric TNFSF ligand technology is protected by an issued US patent, US 7,300,774 B1, entitled, “Multimeric Fusion Proteins of the TNF SuperFamily Ligands” and issued on Nov. 27, 2007. The lead molecule is multimeric, soluble CD40 ligand (CD40L), where CD40L is a master switch for initiating immune responses.

For further details, visit the company’s website: [www.multimericbio.com](http://www.multimericbio.com)

**About Multimeric Biotherapeutics, Inc.**

Multimeric Biotherapeutics, Inc. is a biotech company focused on applying CD40L and other TNF SuperFamily ligands for the prevention and treatment of disease. It uses its novel technology to create next-generation vaccines and tumor immunotherapies. More information is available at [www.multimericbio.com](http://www.multimericbio.com) . Contact us at [info@multimericbio.com](mailto:info@multimericbio.com)